NPS Downsizes, Seeks Partners To Develop Preos And Teduglutide
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will reduce its workforce to 35 and focus on outsourcing and partnering to bring the two Phase III compounds to market.
You may also be interested in...
Swiss Pharma Nycomed Agrees To Market NPS’ Gattex Ex-U.S.
NPS gets $35 million upfront, potential $150 million in milestones and double-digit royalties from Nycomed for Gattex.
Swiss Pharma Nycomed Agrees To Market NPS’ Gattex Ex-U.S.
NPS gets $35 million upfront, potential $150 million in milestones and double-digit royalties from Nycomed for Gattex.
NPS Estimates Gattex Initial Market At $150 Million To $250 Million
Company is seeking a pre-NDA meeting with FDA to discuss mixed top-line results from a Phase III study of the agent in short bowel syndrome.